Cohort Profile: Virus Watch—understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour

• Extract
• Supplementary data

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra^® in combination with Truvada^® for HIV post-exposure prophylaxis (MiPEP Trial)

• Abstract

Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men

• Abstract
• Supplementary data

Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure

• Abstract
• Supplementary data

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study

• Abstract

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring Get access

• Abstract
• Supplementary data

Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy? Get access

• Abstract

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor Get access

• Abstract
• Supplementary data

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study Get access

• Abstract
• Supplementary data

Factors influencing lopinavir and atazanavir plasma concentration Get access

• Abstract

Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir Get access

• Abstract

The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort Study Get access

• Abstract

JOHN GILSON CHAIR OF OCCUPATIONAL MEDICINE Get access